Background
19th May 2014

AstraZeneca Rejects Final Pfizer Takeover Offer

AstraZeneca, the UK drugs company, has rejected a "final" takeover offer from US drugs firm Pfizer.

Scroll
Article Image Circle Circle


AstraZeneca Rejects Final Pfizer Takeover Offer

AstraZeneca, the UK drugs company, has rejected a “final” takeover offer from US drugs firm Pfizer.

Pfizer had offered £53.50 on Friday but AstraZeneca told Pfizer at the weekend that the price needed to be at least 10% higher, valuing AstraZeneca at about £74 billion.

Pfizer made a new offer of £55 per share, valuing AstraZeneca at about £69 billion, an offer that AstraZeneca’s chairman Leif Johansson said did not meet the price that the US company was told was necessary.

AstraZeneca’s shares fell 14% to £41.45 after news broke of the rejection.

Pfizer’s moves to take over AstraZeneca have been surrounded by controversy, with politicians and unions expressing fears that a takeover would hinder AstraZeneca’s drug research and lead to job losses among the firm’s 6,700-strong UK workforce.

Pfizer planned to create the world’s largest drug company, with its headquarters in New York, but based in the UK for tax purposes – a strategy known as “tax inversion” whereby Pfizer could pay the UK corporate tax rate of 20%, rather than the 35% rate applied in the US.

Johansson said Pfizer’s pursuit had been “fundamentally driven” by the corporate financial benefits, adding that “Pfizer has failed to make a compelling strategic, business or value case.”

Pfizer had said that its improved offer of £55 per share was “final” and could not be increased.


Categories: Articles



Other Articles You Might Like
Arrow

Wealth & Finance International is part of AI Global Media

Discover our 10+ brands covering different sectors
APAC InsiderBUILD MagazineCorporate VisionEU Business NewsGHP NewsAcquisition InternationalNew World ReportMEA MarketsCEO MonthlySME NewsLUXlife MagazineInnovation in BusinessThe Business Concept APAC InsiderBUILD MagazineCorporate VisionEU Business NewsGHP NewsAcquisition InternationalNew World ReportMEA MarketsCEO MonthlySME NewsLUXlife MagazineInnovation in BusinessThe Business Concept